🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 14 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
27/10/2021 33,42 34,00 32,74 33,09 -1,72% 3,77% 204.400
26/10/2021 34,70 34,99 33,45 33,67 -2,07% 4,44% 248.700
25/10/2021 35,07 35,34 34,21 34,38 -2,69% 3,22% 244.100
22/10/2021 35,10 35,47 34,41 35,33 +0,80% 3,02% 389.700
21/10/2021 34,11 35,26 33,98 35,05 +2,52% 3,75% 372.000
20/10/2021 35,24 35,60 33,66 34,19 -2,70% 5,49% 346.200
19/10/2021 34,78 35,47 34,28 35,14 +2,60% 3,42% 199.000
18/10/2021 34,04 35,08 33,68 34,25 -0,41% 4,13% 431.100
15/10/2021 33,27 35,15 32,57 34,39 +5,78% 7,75% 470.900
14/10/2021 31,70 32,77 31,65 32,51 +3,60% 3,53% 235.800
13/10/2021 31,96 31,97 31,09 31,38 -0,88% 2,75% 181.800
12/10/2021 32,20 32,37 31,34 31,66 -0,63% 3,20% 345.000
11/10/2021 31,30 32,13 30,90 31,86 +1,21% 3,93% 228.700
08/10/2021 32,77 32,77 31,27 31,48 -4,69% 4,58% 247.200
07/10/2021 34,06 34,55 32,97 33,03 -1,93% 4,64% 516.300
06/10/2021 33,47 34,25 33,39 33,68 +0,18% 2,57% 266.300
05/10/2021 33,85 34,20 33,22 33,62 -0,24% 2,88% 255.200
04/10/2021 34,77 35,29 33,41 33,70 -4,34% 5,41% 564.200
01/10/2021 34,70 35,88 34,09 35,23 +1,03% 5,14% 452.500
30/09/2021 34,63 35,28 33,90 34,87 +1,04% 3,98% 645.200
29/09/2021 36,39 36,40 34,42 34,51 -4,22% 5,44% 598.800
28/09/2021 37,31 37,90 36,00 36,03 -4,38% 5,09% 672.100
27/09/2021 36,02 37,99 35,14 37,68 +4,75% 7,91% 781.600
24/09/2021 36,75 37,60 35,18 35,97 -2,76% 6,60% 1.284.200
23/09/2021 35,84 37,33 35,16 36,99 +2,64% 6,05% 927.900
22/09/2021 36,33 38,00 35,96 36,04 +0,08% 5,62% 1.427.300
21/09/2021 35,60 36,19 34,94 36,01 +2,56% 3,53% 365.000
20/09/2021 35,49 36,14 34,56 35,11 -3,52% 4,45% 474.700
17/09/2021 34,25 36,89 33,75 36,39 +10,17% 9,17% 1.681.400
16/09/2021 33,40 33,82 32,31 33,03 -1,02% 4,52% 347.800